TVR is one of the best PI even compared to other PIs under development. VX-222 is the best non-nuc polymerase inhibitor.
BMY has an excellent NS5A inhibitor. Yet when it is combined with their PI, the combo can achieve an SVR rate of only 2 out of 9 (22%) hcv gt 1a infected patients after dosing 24 weeks (NEJM just published). Most all-oral drugs have difficulty with difficult-to-treat patients.
Oral drugs have a large relapse rate. They have to be tested for UND 24 or 48 weeks following the end of dosing. There are only two or three drug combos which have SVR24 data. It is difficult to predict what the outcome will be for any all-oral drugs because of dearth of data.
In their phase 2 Electron study Pharmasset's (now Gilead's) chain terminating polymerase inhibitor, GS 7977, acheived HCV RNA negativity in 35/35 genotype 1 patients at 4 weeks of just GS 7977 and RBV. No interferon. Nothing in VRTX's or anyone else's stable has produced anything like these results. Telaprevir and VX-222 couldn't do that with interferon and RBV at any point, even at EOT, in IFN naive patients. Not yet game over but tick tock.
I do not think it is 35/35. It is only 1 arm of 35 patients, 10/10. Someone correct me if I am wrong. These patients may belong to the relatively easy to cure group in Genotype 1, in my opinion. In addition, it is RVR, not SVR.